BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Sanofi-Aventis (SNY): 100% Score on a Ben Graham Value Model]]>http://www.bloggingstocks.com/2011/04/01/sanofi-aventis-sny-100-score-on-a-ben-graham-value-model/http://www.bloggingstocks.com/2011/04/01/sanofi-aventis-sny-100-score-on-a-ben-graham-value-model/http://www.bloggingstocks.com/2011/04/01/sanofi-aventis-sny-100-score-on-a-ben-graham-value-model/#commentsFiled under: , ,

Sanofi Aventis (SNY) logo"Sanofi-Aventis (SNY), a pharmaceutical products company, is a buy based on our 'Benjamin Graham value' model," says John Reese who assesses stocks based on the investment criteria of numerous "legendary" investors.

The editor of Validea, explains, "Indeed, the stock earns a 100% score, meeting all of the investment criteria we review in for this value-oriented screen.

Continue reading Sanofi-Aventis (SNY): 100% Score on a Ben Graham Value Model

Sanofi-Aventis (SNY): 100% Score on a Ben Graham Value Model originally appeared on BloggingStocks on Fri, 01 Apr 2011 12:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>ben graham stocksdrug stocksjohn reeseJohnReesepharma stockspharmaceutical stockssanofi-aventisSnysteven halpernThestockadvisors.comvalideavalue investingvalue stocksFri, 01 Apr 2011 12:00:00 EST<![CDATA[Closing Bell: A Double From Lows (CAGC, CMCSA, DELL, DSCO, FDO, GENZ, SNY)]]>http://www.bloggingstocks.com/2011/02/16/closing-bell-a-double-from-lows-cagc-cmcsa-dell-dsco-fdo/http://www.bloggingstocks.com/2011/02/16/closing-bell-a-double-from-lows-cagc-cmcsa-dell-dsco-fdo/http://www.bloggingstocks.com/2011/02/16/closing-bell-a-double-from-lows-cagc-cmcsa-dell-dsco-fdo/#commentsFiled under: , , ,

The FOMC Minutes offered a slight economic upgrade today. A large draw in oil inventories and word that Iran was sending two warships through the Suez canal to go to the Mediterranean spooked investors for a bit. The S&P is now up 100% from the lows of March 2009.

Here were today's unofficial closing bell levels:

Dow Jones 12,288.17 +61.53 (0.50%)
S&P 500 1,336.32 +8.31 (0.63%)
Nasdaq 2,825.56 +21.21 (0.76%)

Continue reading Closing Bell: A Double From Lows (CAGC, CMCSA, DELL, DSCO, FDO, GENZ, SNY)

Closing Bell: A Double From Lows (CAGC, CMCSA, DELL, DSCO, FDO, GENZ, SNY) originally appeared on BloggingStocks on Wed, 16 Feb 2011 16:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>CAGCDELLDSCOFDOGENZSNYWed, 16 Feb 2011 16:20:00 EST<![CDATA[U.S. Stock Futures Up After Dell Reports Upbeat Earnings]]>http://www.bloggingstocks.com/2011/02/16/u-s-stock-futures-up-after-dell-reports-upbeat-earnings/http://www.bloggingstocks.com/2011/02/16/u-s-stock-futures-up-after-dell-reports-upbeat-earnings/http://www.bloggingstocks.com/2011/02/16/u-s-stock-futures-up-after-dell-reports-upbeat-earnings/#commentsFiled under: , , , , ,

U.S. stock futures are higher Wednesday morning as Sanofi-Aventis (SNY) agreed to purchase Genzyme (GENZ) and Dell (DELL) reported upbeat quarterly earnings.

Futures on the Dow Jones Industrial Average gained 30 points to 12,232 and S&P 500 futures rose 4.20 points to 1,330.50. Nasdaq 100 futures gained 5.50 points to 2,387.

U.S. stocks closed lower Tuesday, with the Dow Jones Industrial Average dropping 0.34% to close at 12,227.

Continue reading U.S. Stock Futures Up After Dell Reports Upbeat Earnings

U.S. Stock Futures Up After Dell Reports Upbeat Earnings originally appeared on BloggingStocks on Wed, 16 Feb 2011 08:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>dell earningsfdofeaturedfomcgenzproducer price indexsanofi-aventisSanofi-Aventis takeover genzymesnyWed, 16 Feb 2011 08:30:00 EST<![CDATA[Closing Bell: Lack of Catalysts (WMT, GENZ, SNY, LLNW, DELL, GLD, NYX)]]>http://www.bloggingstocks.com/2011/02/15/closing-bell-lack-of-catalysts-wmt-genz-sny-llnw-dell-gld/http://www.bloggingstocks.com/2011/02/15/closing-bell-lack-of-catalysts-wmt-genz-sny-llnw-dell-gld/http://www.bloggingstocks.com/2011/02/15/closing-bell-lack-of-catalysts-wmt-genz-sny-llnw-dell-gld/#commentsFiled under: , , ,

Republicans are seeking an extra $61 billion in budget cuts. Auto sales were seen as having another great year. Homebuilders remain pessimistic and talk of food inflation keeps going on. Even the huge sells from Warren Buffett in his newest holdings failed to inspire.

Here were today's unofficial closing bell levels:

Dow Jones 12,226.64 -41.55 (-0.34%)
S&P 500 1,328.02 -4.30 (-0.32%)
Nasdaq 2,804.35 -12.83 (-0.46%)

Continue reading Closing Bell: Lack of Catalysts (WMT, GENZ, SNY, LLNW, DELL, GLD, NYX)

Closing Bell: Lack of Catalysts (WMT, GENZ, SNY, LLNW, DELL, GLD, NYX) originally appeared on BloggingStocks on Tue, 15 Feb 2011 16:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>DELLGLDLLNWNYXSNYWMTTue, 15 Feb 2011 16:00:00 EST<![CDATA[U.S. Stock Futures Signal Lower Start on Wall Street]]>http://www.bloggingstocks.com/2011/02/09/u-s-stock-futures-signal-lower-start-on-wall-street/http://www.bloggingstocks.com/2011/02/09/u-s-stock-futures-signal-lower-start-on-wall-street/http://www.bloggingstocks.com/2011/02/09/u-s-stock-futures-signal-lower-start-on-wall-street/#commentsFiled under: , , , , , , , ,

U.S. stock futures are lower Wednesday morning as investors await comments from Federal Reserve Chairman Ben Bernanke. Futures for the Dow Jones Industrial Average dropped 22 points to 12,174.00, while those for the S&P 500 index declined 4.9 points to 1,316.80. Futures for the Nasdaq 100 index fell 7.50 points to 2,355.25.

U.S. stocks closed higher Tuesday, with the Dow gaining 0.59% to close at 12,233.

MetLife (MET) is expected to post Q4 EPS of $1.10 on revenue of $13.50 billion. Coca-Cola (KO) is projected to report Q4 EPS of 72 cents on revenue of $9.75 billion. Northrop Grumman (NOC) is projected to report its Q4 earnings at $1.01 per share on revenue of $8.80 billion.

Continue reading U.S. Stock Futures Signal Lower Start on Wall Street

U.S. Stock Futures Signal Lower Start on Wall Street originally appeared on BloggingStocks on Wed, 09 Feb 2011 08:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>allstate earningsBen Bernankecscodisney earningsfeaturedkosanofi aventis earningssnytake two earningsttwowfmiwhole foods earningsWed, 09 Feb 2011 08:30:00 EST<![CDATA[Sanofi-Aventis Breast Cancer Drug Fails]]>http://www.bloggingstocks.com/2011/01/28/sanofi-aventis-breast-cancer-drug-fails/http://www.bloggingstocks.com/2011/01/28/sanofi-aventis-breast-cancer-drug-fails/http://www.bloggingstocks.com/2011/01/28/sanofi-aventis-breast-cancer-drug-fails/#commentsFiled under: , , ,

SNY logoSanofi-Aventis (SNY - option chain) stock is trading lower today after the company said last night that its experimental breast cancer treatment iniparib failed to meet its goal in a Phase 3 study. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on SNY.

This morning, SNY opened at $33.83. So far today the stock has hit a high of $34.01 and a low of $33.29. As of 12:30, SNY is trading at $33.41, down $1.84 (-5.2%). The chart for SNY looks bullish and S&P gives SNY a positive 4 STARS (out of 5) buy ranking.

Continue reading Sanofi-Aventis Breast Cancer Drug Fails

Sanofi-Aventis Breast Cancer Drug Fails originally appeared on BloggingStocks on Fri, 28 Jan 2011 14:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Breast CancerinthenewsInvestors ObserveroptionsSanofi-AventisSNYFri, 28 Jan 2011 14:00:00 EST<![CDATA[Eli Lilly Likely to Remain Limp]]>http://www.bloggingstocks.com/2010/11/24/lilly-likely-to-remain-limp/http://www.bloggingstocks.com/2010/11/24/lilly-likely-to-remain-limp/http://www.bloggingstocks.com/2010/11/24/lilly-likely-to-remain-limp/#commentsFiled under: , , ,

Eli Lilly logoAlthough short-term news may seem bright for Eli Lilly & Co. (LLY), the broader picture for the company looks flat. Having dropped from an average share price in the $53 range over two years ago, to a current average share value hovering near $35, investors are signaling that the long range forecast for Lilly is unexciting at best.

It appears that Lilly shall be buoyed in the near term by the recent FDA approval of testosterone replacement therapy Axiron for sale in the U.S. Lilly purchased rights to Axiron from Australian firm, Acrux for an initial payment of $50 million plus $3 million based on the transfer of manufacturing assets.

Continue reading Eli Lilly Likely to Remain Limp

Eli Lilly Likely to Remain Limp originally appeared on BloggingStocks on Wed, 24 Nov 2010 15:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AcruxAxironEli LillyGSKinthenewsLLYreplacement therapySNYtestosteronetopical treatmenttopical-creamWed, 24 Nov 2010 15:40:00 EST<![CDATA[Closing Bell: Dollar and Terror Kick Start the Week Off Weak (ISLN, MSFT, GENZ, SNY, AXP, ACTL, MSCC, PFE)]]>http://www.bloggingstocks.com/2010/10/04/closing-bell-dollar-and-terror-kick-off-week-weak-isln-msft/http://www.bloggingstocks.com/2010/10/04/closing-bell-dollar-and-terror-kick-off-week-weak-isln-msft/http://www.bloggingstocks.com/2010/10/04/closing-bell-dollar-and-terror-kick-off-week-weak-isln-msft/#commentsFiled under: , ,

Stocks started the week off in the red on a key tech downgrade, and as the U.S. dollar rose against some key currencies. Frankly, today felt like a day where the real answer was "more sellers than buyers" over a key catalyst, even considering a EU terror alert. The end of the TARP program marked more sentiment than any real event.

Here were the unofficial closing bell levels:

Dow Jones 10,751.27 -78.41 (-0.72%)
S&P 500 1,137.03 -9.21 (-0.80%)
Nasdaq 2,344.52 -26.23 (-1.11%)

Top Analyst Calls
Best & Worst DJIA Stocks

Continue reading Closing Bell: Dollar and Terror Kick Start the Week Off Weak (ISLN, MSFT, GENZ, SNY, AXP, ACTL, MSCC, PFE)

Closing Bell: Dollar and Terror Kick Start the Week Off Weak (ISLN, MSFT, GENZ, SNY, AXP, ACTL, MSCC, PFE) originally appeared on BloggingStocks on Mon, 04 Oct 2010 16:10:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>ACTLAXPGENZISLNMSCCPFESNYMon, 04 Oct 2010 16:10:00 EST<![CDATA[Closing Bell: Traders Put The Risk Back On (MSFT, LNG, OXGN, ARST, HPQ, GENZ, SNY, PCG)]]>http://www.bloggingstocks.com/2010/09/13/closing-bell-traders-put-the-risk-back-on-msft-lng-oxgn-ars/http://www.bloggingstocks.com/2010/09/13/closing-bell-traders-put-the-risk-back-on-msft-lng-oxgn-ars/http://www.bloggingstocks.com/2010/09/13/closing-bell-traders-put-the-risk-back-on-msft-lng-oxgn-ars/#commentsFiled under: ,

Today was another up day, mostly thanks to the new Basel III banking accords showing that most banks are actually not in need of fresh capital any time in the immediate future. We also saw Warren Buffett refute that there is a double-dip recession and we also had a slightly less-atrocious August Treasury deficit than expected. This was a day where traders began putting back on the risk trade.

Here were today's closing bell levels:

DJIA
S&P500
NASDAQ

Continue reading Closing Bell: Traders Put The Risk Back On (MSFT, LNG, OXGN, ARST, HPQ, GENZ, SNY, PCG)

Closing Bell: Traders Put The Risk Back On (MSFT, LNG, OXGN, ARST, HPQ, GENZ, SNY, PCG) originally appeared on BloggingStocks on Mon, 13 Sep 2010 17:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>ARSTGENZHPQMSFTOXGNPCGSNYMon, 13 Sep 2010 17:20:00 EST<![CDATA[Analyst Calls: AZO, CERN, CIS, INTC, LMT, LULU, NE, RTN, SNY, TXN ...]]>http://www.bloggingstocks.com/2010/08/30/analyst-upgrades-downgrades/http://www.bloggingstocks.com/2010/08/30/analyst-upgrades-downgrades/http://www.bloggingstocks.com/2010/08/30/analyst-upgrades-downgrades/#commentsFiled under: , , , , , , ,

Analyst Upgrades

  • BMO Capital upgraded Noble Energy (NE) to outperform from market perform and raised its target to $85 from $78. The firm upgraded Noble based on Niobrara field potential and record-breaking reserve potential at the Leviathan prospect.
  • Wells Fargo upgraded Raytheon (RTN) to outperform from market perform based on relative valuation, strong balance sheet and International sales exposure.
  • ThinkEquity upgraded Cerner (CERN) to buy from hold based on valuation and EMR momentum. The firm raised its price target on shares to $86 from $80.
  • Sanofi-Aventis (SNY) was upgraded to buy from hold at Societe Generale.
  • Cavium Networks (CAVM) was upgraded to outperform from market perform at JMP Securities.
  • CSG Systems (CSGS) was upgraded to outperform from perform at Oppenheimer.

Continue reading Analyst Calls: AZO, CERN, CIS, INTC, LMT, LULU, NE, RTN, SNY, TXN ...

Analyst Calls: AZO, CERN, CIS, INTC, LMT, LULU, NE, RTN, SNY, TXN ... originally appeared on BloggingStocks on Mon, 30 Aug 2010 12:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>analyst upgradesANDEAutoZoneAZOCAVMCERNCISCSGSdowngradesHXLinitiationsIntelinthenewsLMTLockheed MartinLULULululemonNENoble EnergyRaytheonRTNSNYTexas InstrumentsTIBXTXNZOLTMon, 30 Aug 2010 12:00:00 EST<![CDATA[Genzyme Rejects Sanofi-Aventis's Buyout Proposal]]>http://www.bloggingstocks.com/2010/08/30/genzyme-rejects-sanofi-aventiss-buyout-proposal/http://www.bloggingstocks.com/2010/08/30/genzyme-rejects-sanofi-aventiss-buyout-proposal/http://www.bloggingstocks.com/2010/08/30/genzyme-rejects-sanofi-aventiss-buyout-proposal/#commentsFiled under: ,

Over the weekend, French pharmaceutical firm Sanofi-Aventis (SNY) made its attempt to take over biotech firm Genzyme (GENZ) official. SNY offered $69 per GENZ share, which is slightly more than a dollar higher over GENZ's Friday close. The total value of the offer comes to $18.5 billion.

Although the offer isn't much more than Friday's close, it is 38% higher than GENZ's July 1 close. This is when speculation cropped up about a potential buyout offer from SNY. GENZ turned down the offer, noting that SNY was undervaluing the company.

Continue reading Genzyme Rejects Sanofi-Aventis's Buyout Proposal

Genzyme Rejects Sanofi-Aventis's Buyout Proposal originally appeared on BloggingStocks on Mon, 30 Aug 2010 10:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotechbuyoutinthenewspharmaceuticalsSanofi AventisSNYtakeoverMon, 30 Aug 2010 10:00:00 EST<![CDATA[Analyst Calls: ALU, CHL, EXC, GENZ, KO, NDSN, NSW, SJM, TXN ...]]>http://www.bloggingstocks.com/2010/08/02/analyst-upgrades-downgrades/http://www.bloggingstocks.com/2010/08/02/analyst-upgrades-downgrades/http://www.bloggingstocks.com/2010/08/02/analyst-upgrades-downgrades/#commentsFiled under: , , , , , ,

Analyst Upgrades

  • JPMorgan upgraded Coca-Cola (KO) to overweight from neutral due to valuation and expectations that developed market volume should improve. The firm raised its target price for shares to $66.
  • BB&T upgraded Nordson (NDSN) to buy from hold and has an $82 price target on the stock. The firm believes certain drivers of Nordson's Advanced Tech unit are becoming more secular vs. cyclical and that the company's EBIT margins can go higher.
  • Credit Suisse upgraded Embraer (ERJ) to outperform from underperform, citing the positive announcements from the Famborough Air Show. The firm raised its price target to $37 from $21.
  • Universal Health (UHS) was upgraded to outperform from sector perform at RBC Capital.
  • Mead Johnson (MJN) was upgraded to conviction buy from buy at Goldman.
  • Coventry Health (CVH) was upgraded to outperform from market perform at Leerink.

Continue reading Analyst Calls: ALU, CHL, EXC, GENZ, KO, NDSN, NSW, SJM, TXN ...

Analyst Calls: ALU, CHL, EXC, GENZ, KO, NDSN, NSW, SJM, TXN ... originally appeared on BloggingStocks on Mon, 02 Aug 2010 11:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>ALUChina MobilCHLCHUCoca-ColaCVHDIODdowngradesERJEXCFCSGenzymeinitiationsinthenewsKOMJNMUNDSNNews Corp.NWSQEPSEEDSJMSmuckerSNYSTANSTMTexas InstrumentsTWERTXNUHSMon, 02 Aug 2010 11:20:00 EST<![CDATA[Genzyme Lifted by Takeover Speculation]]>http://www.bloggingstocks.com/2010/07/29/genzyme-lifted-by-takeover-speculation/http://www.bloggingstocks.com/2010/07/29/genzyme-lifted-by-takeover-speculation/http://www.bloggingstocks.com/2010/07/29/genzyme-lifted-by-takeover-speculation/#commentsFiled under: , , , , , ,

Genzyme (GENZ - option chain) shares are rising today on a report in the Wall Street Journal which says that Sanofi-Aventis SA (SNY) could make a formal takeover offer to GENZ's board that could be worth about $20 billion. SNY declined to comment on the report. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on GENZ.

GENZ opened this morning at $70.31. So far today the stock has hit a low of $69.97 and a high of $70.97. As of 11:55, GENZ is trading at $70.09 up $2.09 (3.1%). The chart for GENZ looks bullish and S&P gives GENZ a positive 4 STARS (out of 5) buy ranking.

Continue reading Genzyme Lifted by Takeover Speculation

Genzyme Lifted by Takeover Speculation originally appeared on BloggingStocks on Thu, 29 Jul 2010 13:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>dealGENZGenzymeinthenewsInvestors ObserveroptionsrumorsSanofi-AventisSNYtakeoverThu, 29 Jul 2010 13:30:00 EST<![CDATA[Options Update: BP Overall Volatility Decreases]]>http://www.bloggingstocks.com/2010/07/27/options-bp-overall-volatility-decreases-loss-genzyme/http://www.bloggingstocks.com/2010/07/27/options-bp-overall-volatility-decreases-loss-genzyme/http://www.bloggingstocks.com/2010/07/27/options-bp-overall-volatility-decreases-loss-genzyme/#commentsFiled under: , , ,

BP (BP) closed up $1.79 Monday to $38.65. The company reported a $17 billion loss Tuesday morning and announced it has replaced CEO Tony Hayward with Bob Dudley. Overall option implied volatility of 51 is below a level of 78 from June 28, according to Track Data, suggesting decreasing price movement.

Genzyme (GENZ) closed up $4.86 to $67.38. Sanofi-Aventis (SNY), GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) may be interested in making a play for GENZ, reports the Wall Street Journal. Overall option implied volatility of 40 is above GENZ 26-week average of 31, according to Track Data, suggesting larger price movement.

Update is by Stock Specialist Paul Foster of theflyonthewall.com.

Options Update: BP Overall Volatility Decreases originally appeared on BloggingStocks on Tue, 27 Jul 2010 09:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>bpgenzgskinthenewsjnjsnyTue, 27 Jul 2010 09:00:00 EST<![CDATA[Goldman Sachs Targets Allergan as Takeover Candidate]]>http://www.bloggingstocks.com/2010/07/13/goldman-sachs-targets-allergan-as-takeover-candidate/http://www.bloggingstocks.com/2010/07/13/goldman-sachs-targets-allergan-as-takeover-candidate/http://www.bloggingstocks.com/2010/07/13/goldman-sachs-targets-allergan-as-takeover-candidate/#commentsFiled under: , ,

If you're interested on taking a bet on a potential high-flyer, you might want to take a look at Allergan (AGN).

Goldman Sachs recently said they expect more M&A activity in pharmaceutical and that Allergan is a prime candidate for a takeover. Sanofi-Aventis (SNY) and Eli Lilly & Co. (LLY) are two companies analysts are speculating may be interested in acquiring Allergan.

Goldman also upgraded its price target for Allergan on its Conviction Buy List from $78 to $81.

Continue reading Goldman Sachs Targets Allergan as Takeover Candidate

Goldman Sachs Targets Allergan as Takeover Candidate originally appeared on BloggingStocks on Tue, 13 Jul 2010 13:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>aclagnalconallerganEli LillyfeaturedGoldman Sachsjnjjohnson and johnsonllySanofi-AventissnyTue, 13 Jul 2010 13:30:00 EST<![CDATA[Allergan, BJ's Wholesale and Others Heating Up in Google]]>http://www.bloggingstocks.com/2010/07/02/allergan-bjs-wholesale-and-others-heating-up-in-google/http://www.bloggingstocks.com/2010/07/02/allergan-bjs-wholesale-and-others-heating-up-in-google/http://www.bloggingstocks.com/2010/07/02/allergan-bjs-wholesale-and-others-heating-up-in-google/#commentsFiled under:

It appears that U.S.-based drug makers and cigarette companies caught the attention of traders Tuesday -- at least, that's what they're searching for.

If you want to know what stocks traders are interested in right now at this very second, you need look no further than what's hot in Google.

Here's what's hot Friday:

Continue reading Allergan, BJ's Wholesale and Others Heating Up in Google

Allergan, BJ's Wholesale and Others Heating Up in Google originally appeared on BloggingStocks on Fri, 02 Jul 2010 16:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>agnallerganbiibbiogenbjBJs WholesalegoogleinthenewsSanofi-Aventissnyvector groupvgrFri, 02 Jul 2010 16:30:00 EST<![CDATA[Wall Street Ignoring Big Pharma -- Should You?]]>http://www.bloggingstocks.com/2010/06/28/wall-street-ingoring-big-pharma-should-you/http://www.bloggingstocks.com/2010/06/28/wall-street-ingoring-big-pharma-should-you/http://www.bloggingstocks.com/2010/06/28/wall-street-ingoring-big-pharma-should-you/#commentsFiled under: , , , ,

In its weekend edition, Barron's Andrew Bary wonders whether Big Pharma's punishment on Wall Street has gone too far. The sector has fallen out of favor with Wall Street and now has one of the lowest price/earnings ratios of any major sector of the stock market, Bary writes.

Investors are staying away from the large pharmaceutical companies ahead of their looming patent cliff, when blockbuster drugs like Lipitor, Plavix and Singulair lose patent protection and lose most of the sales from these drugs to generics. Investors also fear the companies don't have enough new drugs in the pipeline to make up for the lost sales, which could mean big hits to earnings.

But when the Street writes off one of the world's most important industries and with valuations at all-time lows, investors ought to take notice, Bary says. Especially when the average dividend yield of the big drugmakers is 4.8%.

Continue reading Wall Street Ignoring Big Pharma -- Should You?

Wall Street Ignoring Big Pharma -- Should You? originally appeared on BloggingStocks on Mon, 28 Jun 2010 14:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>aznbig pharmabmyfeaturedgskinthenewsllymrknvspatent cliffpfepharmaceuticalsrhhbysnyMon, 28 Jun 2010 14:30:00 EST<![CDATA[Sanofi-Aventis Dips on Eloxatin Patent Settlements]]>http://www.bloggingstocks.com/2010/04/06/sanofi-aventis-dips-on-eloxatin-patent-settlements/http://www.bloggingstocks.com/2010/04/06/sanofi-aventis-dips-on-eloxatin-patent-settlements/http://www.bloggingstocks.com/2010/04/06/sanofi-aventis-dips-on-eloxatin-patent-settlements/#commentsFiled under: , , ,

SNY logoSanofi-Aventis (SNY - option chain) stock is trading lower today after the company announced this morning that it has settled patent infringement suits with Hospira (HSP) and Par Pharmaceutical Companies (PRX) related to certain generic versions of its cancer treatment Eloxatin. The settlements will stop HSP and PRX from selling generic versions of Eloxatin from late-June until August 2012. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on SNY.

This morning, SNY opened at $36.51. So far today the stock has hit a high of $36.69 and a low of $36.43. As of 12:10, SNY is trading at $36.69, down $0.51 (-1.4%). The chart for SNY looks neutral and S&P gives SNY a neutral 3 STARS (out of 5) hold ranking.

Continue reading Sanofi-Aventis Dips on Eloxatin Patent Settlements

Sanofi-Aventis Dips on Eloxatin Patent Settlements originally appeared on BloggingStocks on Tue, 06 Apr 2010 13:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>HospiraHSPInvestors ObserveroptionsPar PharmaceuticalspatentPRXSanofi-AventisSNYTue, 06 Apr 2010 13:20:00 EST<![CDATA[Analyst Upgrades, Downgrades and Initiations: AMTD, AOL, CHTT, CSC, IMAX, SAIA, WRC ...]]>http://www.bloggingstocks.com/2009/12/22/analyst-upgrades-downgrades-and-initiations/http://www.bloggingstocks.com/2009/12/22/analyst-upgrades-downgrades-and-initiations/http://www.bloggingstocks.com/2009/12/22/analyst-upgrades-downgrades-and-initiations/#commentsFiled under: , ,

Analyst Upgrades

  • Keefe Bruyette upgraded TD AmeriTrade (AMTD) to outperform from market perform on valuation following the recent sell-off in shares. The firm has a $22.50 price target on the stock.
  • Stifel upgraded Saia (SAIA) to buy from hold based on valuation, operating leverage and increased possibility of a large industry consolidation event in the next few months. The firm has an $18 target on the stock.
  • Citigroup upgraded Atlas Pipeline Holdings (AHD) to hold from sell to reflect valuation and an improved outlook for commodity prices. The firm raised its target on shares to $6 from 50 cents.
  • Manpower (MAN) was upgraded to buy from neutral at BofA/Merrill.
  • IAMGOLD (IAG) was upgraded to buy from neutral at UBS.

Continue reading Analyst Upgrades, Downgrades and Initiations: AMTD, AOL, CHTT, CSC, IMAX, SAIA, WRC ...

Analyst Upgrades, Downgrades and Initiations: AMTD, AOL, CHTT, CSC, IMAX, SAIA, WRC ... originally appeared on BloggingStocks on Tue, 22 Dec 2009 11:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AHDAMTDanalyst upgradesAOLATHRCHTTCPRTCSCdowngradesENOCFOGIGMIAGIMAXinitiationsinthenewsMANNRGPPVHSAIASNYWRCTue, 22 Dec 2009 11:20:00 EST<![CDATA[You can profit from James Altucher's insanity]]>http://www.bloggingstocks.com/2009/12/12/you-can-profit-from-james-altuchers-insanity/http://www.bloggingstocks.com/2009/12/12/you-can-profit-from-james-altuchers-insanity/http://www.bloggingstocks.com/2009/12/12/you-can-profit-from-james-altuchers-insanity/#commentsFiled under: , , , ,

James Altucher is a financial journalist for The Wall Street Journal and founder of Stockpickr.com. His articles cover every angle of the market; he also stars in feature videos with other financial luminaries. He is the author of Trade Like a Hedge Fund, Trade Like Warren Buffett, SuperCa$h, and The Forever Portfolio.

He has taken a controversial path lately with numerous articles in the New York Post and Huffington Post. Some articles include: "Global Warming Is a Myth," "Should Insider Trading Be Made Legal?" "School of Hard Cash," "The Internet Is Dead (as an Investment)," and "5 Myths the Recession Taught Us."

Rumors of a new addition to the James Altucher library have entered the blogosphere, so I met with James to discuss a possible new book and the response from his recent aggressive views on finance and the stock market.

Continue reading You can profit from James Altucher's insanity

You can profit from James Altucher's insanity originally appeared on BloggingStocks on Sat, 12 Dec 2009 16:10:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Amazon.comAMZNAOLCamecocapitalismCCJclimate changeDailyFinanceday tradingFacebookForever PortfolioFred WilsonGlaxoSmithKlineglobal warmingGOOGGoogleGSKhedge fundsHuffington Postinsider tradinginstitutional investingJames AltucherMicrosoftMSFTnaked short sellingnaked shortingNew York PostNews Corp. NWSPCLNPricelinerecessionSanofiAventisSNYswine fluTime WarnerTrade Like a Hedge FundTrade Like Warren BuffettTwitterTWXSat, 12 Dec 2009 16:10:00 EST